amantadine has been researched along with Fatigue in 54 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Fatigue: The state of weariness following a period of exertion, mental or physical, characterized by a decreased capacity for work and reduced efficiency to respond to stimuli.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 9.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS." | 9.27 | Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018) |
| "One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS." | 9.17 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS)." | 9.16 | Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. ( Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakeri, H, 2012) |
| "We investigated the effect of amantadine on cognitive processing in patients with multiple sclerosis (MS) and fatigue with objective electrophysiological measures." | 9.09 | Amantadine influences cognitive processing in patients with multiple sclerosis. ( Hauser, U; Heinze, HJ; Sailer, M; Schoenfeld, MA; Smid, HG, 2000) |
| "Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS." | 9.08 | The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996) |
| "Because amantadine has been shown to reduce fatigue in patients with multiple sclerosis, we performed a double-blind, placebo-controlled study to assess its efficacy in the disabling symptom of post-polio fatigue." | 9.08 | A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. ( Dalakas, MC; Dambrosia, JM; Stein, DP, 1995) |
| "To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue." | 9.08 | Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995) |
| "In a double-blind placebo-controlled crossover study of ten patients with multiple sclerosis, we found amantadine hydrochloride therapy to be effective in improving fatigability in six." | 9.06 | Amantadine, fatigue, and multiple sclerosis. ( Appenzeller, O; Rosenberg, GA, 1988) |
| "We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo." | 9.05 | Amantadine therapy for fatigue in multiple sclerosis. ( Murray, TJ, 1985) |
| "To determine the effectiveness and safety of amantadine in treating fatigue in people with MS." | 8.84 | Amantadine for fatigue in multiple sclerosis. ( Branãs, P; D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2007) |
| "Randomised, placebo or other drugs-controlled, double-blind trials of amantadine in MS people with fatigue." | 8.82 | Amantadine for fatigue in multiple sclerosis. ( D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2003) |
| "Amantadine is sometimes used to treat fatigue in multiple sclerosis." | 8.02 | Delayed amantadine toxicity causing apparent progression of multiple sclerosis. ( Bradley, L, 2021) |
| "Acupuncture appears to be associated with benefits for a proportion of patients with fatigue who are resistant to conventional drugs such as amantadine, and this finding justifies further research." | 7.79 | Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. ( Bahrami Taghanaki, HR; Foroughipour, M; Khazaei, M; Saeidi, M; Sasannezhad, P; Shoeibi, A, 2013) |
| "Changes in modified fatigue impact scale (MFIS) score and network RS FC were assessed." | 7.01 | Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. ( Colombo, B; Filippi, M; Martinelli, V; Rocca, MA; Valsasina, P, 2021) |
| "Amantadine was not superior to placebo." | 6.72 | Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. ( Garssen, MP; Jacobs, BC; Merkies, IS; Schmitz, PI; van der Meché, FG; van Doorn, PA, 2006) |
| "Fatigue is a common symptom of multiple sclerosis (MS) that is without an effective treatment." | 6.66 | Amantadine treatment of fatigue associated with multiple sclerosis. ( Cohen, RA; Fisher, M, 1989) |
| "The present research was intended to investigate the effectiveness of acupuncture plus amantadine compared with amantadine alone on fatigue in patients with relapsing-remitting MS (RRMS) in the remission stage of the disease." | 5.69 | Effectiveness of acupuncture for fatigue in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial. ( Kazemi, AH; Khodaie, F; Naser Moghadasi, A; Zhao, B, 2023) |
| "Methylphenidate, modafinil, and amantadine are commonly prescribed medications for alleviating fatigue in multiple sclerosis; however, the evidence supporting their efficacy is sparse and conflicting." | 5.41 | Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial. ( Aljarallah, S; Auvray, C; Cordano, C; Creasman, J; Jin, C; Krysko, K; Manguinao, M; McCulloch, C; Morris, B; Mowry, E; Nourbakhsh, B; Revirajan, N; Rutatangwa, A; Waubant, E, 2021) |
| "The study is a randomized, placebo-controlled, crossover, four-sequence, four-period, double-blind, multicenter trial of three commonly used medications for the treatment of MS-related fatigue (amantadine, modafinil, methylphenidate) versus placebo in fatigued subjects with MS." | 5.27 | Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial. ( Nourbakhsh, B; Revirajan, N; Waubant, E, 2018) |
| "One month treatment with amantadine improved fatigue in patients with relapsing-remitting MS as evaluated by MFIS." | 5.17 | Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study. ( Ledinek, AH; Rot, U; Sajko, MC, 2013) |
| "The purpose of this study was to compare the relative efficacy of acetylsalicylic acid (ASA) and amantadine for the treatment of fatigue in multiple sclerosis (MS)." | 5.16 | Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study. ( Ashtari, F; Janghorbani, M; Shaygannejad, V; Zakeri, H, 2012) |
| "We investigated the effect of amantadine on cognitive processing in patients with multiple sclerosis (MS) and fatigue with objective electrophysiological measures." | 5.09 | Amantadine influences cognitive processing in patients with multiple sclerosis. ( Hauser, U; Heinze, HJ; Sailer, M; Schoenfeld, MA; Smid, HG, 2000) |
| "Amantadine hydrochloride and pemoline, both frequently used to treat the fatigue of multiple sclerosis (MS), may also improve attention and other cognitive functions in MS." | 5.08 | The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. ( Coyle, PK; Doscher, C; Geisler, MW; Krupp, LB; Masur, DM; Sliwinski, M, 1996) |
| "To determine the relative efficacy of amantadine, pemoline, and placebo in treatment of multiple sclerosis (MS)-related fatigue." | 5.08 | Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. ( Coyle, PK; Cross, AH; Doscher, C; Grimson, R; Halper, J; Jandorf, L; Johnson, B; Krupp, LB; Miller, A; Morgante, L, 1995) |
| "Because amantadine has been shown to reduce fatigue in patients with multiple sclerosis, we performed a double-blind, placebo-controlled study to assess its efficacy in the disabling symptom of post-polio fatigue." | 5.08 | A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. ( Dalakas, MC; Dambrosia, JM; Stein, DP, 1995) |
| "In a double-blind placebo-controlled crossover study of ten patients with multiple sclerosis, we found amantadine hydrochloride therapy to be effective in improving fatigability in six." | 5.06 | Amantadine, fatigue, and multiple sclerosis. ( Appenzeller, O; Rosenberg, GA, 1988) |
| "We carried out a double blind control study of fatigue in 32 patients with multiple sclerosis, comparing amantadine hydrochloride 100 mg twice a day and placebo." | 5.05 | Amantadine therapy for fatigue in multiple sclerosis. ( Murray, TJ, 1985) |
| "Current limited data suggest that amantadine may be the only drug that has relatively sufficient evidences in treatment of fatigue symptoms in MS." | 4.95 | Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. ( Deng, XY; Wang, L; Yang, TT; Yu, G, 2017) |
| " We included studies investigating pemoline and modafinil in participants with multiple sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue in meta-analysis." | 4.91 | Pharmacological treatments for fatigue associated with palliative care. ( Cuhls, H; Minton, O; Mücke, M; Peuckmann-Post, V; Radbruch, L; Stone, P, 2015) |
| " The effects of amantadine from one randomised, double-blind, placebo-controlled, cross-over trial comparing amantadine with placebo for the treatment of fatigue in 80 people with Guillain-Barré syndrome (GBS) were uncertain for the proportion of people achieving a favourable outcome six weeks post-intervention (odds ratio (OR) 0." | 4.90 | Interventions for fatigue in peripheral neuropathy. ( Garssen, MP; Stockley, RC; van Doorn, PA; White, CM, 2014) |
| " In the completed study, adult patients with relapsing-remitting and secondary progressive MS were exposed to both acetyl L-carnitine 2 grams daily and amantadine 200 mg daily The effects of carnitine on fatigue are unclear." | 4.88 | Carnitine for fatigue in multiple sclerosis. ( Nathwani, S; Rowell, G; Spiwak, R; Tejani, AM; Wasdell, M, 2012) |
| " Studies investigating amantadine, pemoline, and modafinil in participants with Multiple Sclerosis (MS)-associated fatigue and methylphenidate in patients suffering from advanced cancer and fatigue could be used for meta-analysis." | 4.86 | Pharmacological treatments for fatigue associated with palliative care. ( Elsner, F; Krumm, N; Peuckmann, V; Radbruch, L; Trottenberg, P, 2010) |
| "To determine the effectiveness and safety of amantadine in treating fatigue in people with MS." | 4.84 | Amantadine for fatigue in multiple sclerosis. ( Branãs, P; D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2007) |
| "Randomised, placebo or other drugs-controlled, double-blind trials of amantadine in MS people with fatigue." | 4.82 | Amantadine for fatigue in multiple sclerosis. ( D'Amico, R; Giuliani, G; Pucci, E; Solari, A; Taus, C, 2003) |
| " Only amantadine appears to have some proven ability to alleviate the fatigue in MS, though only a proportion of users will obtain benefit and then only some of these patients will benefit sufficiently to take the drug in the long term." | 4.80 | Treatments for fatigue in multiple sclerosis: a rapid and systematic review. ( Brañas, P; Burls, A; Fry-Smith, A; Hyde, C; Jordan, R, 2000) |
| "Amantadine is sometimes used to treat fatigue in multiple sclerosis." | 4.02 | Delayed amantadine toxicity causing apparent progression of multiple sclerosis. ( Bradley, L, 2021) |
| "Acupuncture appears to be associated with benefits for a proportion of patients with fatigue who are resistant to conventional drugs such as amantadine, and this finding justifies further research." | 3.79 | Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study. ( Bahrami Taghanaki, HR; Foroughipour, M; Khazaei, M; Saeidi, M; Sasannezhad, P; Shoeibi, A, 2013) |
| "Changes in modified fatigue impact scale (MFIS) score and network RS FC were assessed." | 3.01 | Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine. ( Colombo, B; Filippi, M; Martinelli, V; Rocca, MA; Valsasina, P, 2021) |
| "Amantadine was not superior to placebo." | 2.72 | Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial. ( Garssen, MP; Jacobs, BC; Merkies, IS; Schmitz, PI; van der Meché, FG; van Doorn, PA, 2006) |
| "Fatigue is a common symptom of multiple sclerosis (MS) that is without an effective treatment." | 2.66 | Amantadine treatment of fatigue associated with multiple sclerosis. ( Cohen, RA; Fisher, M, 1989) |
| "Fatigue is the most common and debilitating symptom in multiple sclerosis (MS) and is believed to be distinctly different from fatigue seen in other chronic conditions." | 2.48 | Fatigue in multiple sclerosis - a brief review. ( Constantinescu, CS; Gran, B; Induruwa, I, 2012) |
| "Fatigue is recognized as one of the most disabling and common symptoms of MS." | 2.44 | Treating fatigue. ( Hum, S; Lapierre, Y, 2007) |
| "Modafinil has been shown to be effective in some studies, and amantadine is an alternative for patients who do not respond to or cannot tolerate modafinil." | 2.42 | Management of fatigue in patients with multiple sclerosis. ( Zifko, UA, 2004) |
| "Fatigue is among the most common, yet least understood, symptoms of multiple sclerosis (MS) [1." | 2.41 | Fatigue in multiple sclerosis. ( Christodoulou, C; Krupp, LB, 2001) |
| "Fatigue is a common symptom in patients with multiple sclerosis." | 2.40 | ['Fatigue' in multiple sclerosis]. ( Hohlfeld, R; Zimmermann, C, 1999) |
| "Multiple sclerosis is a demyelinating disorder of the central nervous system characterized by exacerbations and remissions of symptoms." | 2.38 | Update on multiple sclerosis therapy. ( Mitchell, G, 1993) |
| "The Fatigue Impact Scale for Daily Use (D-FIS) is an eight-item instrument designed to measure subjective daily experience of fatigue." | 1.34 | Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS). ( Antigüedad, AR; Benito-León, J; de Andrés, C; Frades, B; Huete-Antón, B; Martínez-Ginés, ML; Martínez-Martín, P; Meca-Lallana, JE; Rodríguez-García, E; Ruiz-Martínez, J, 2007) |
| "The term "fatigue" has been used for asthenia at rest but also for fatigability during exercise." | 1.31 | [Therapeutic indications for managing symptoms: fatigue]. ( Waubant, E, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (9.26) | 18.7374 |
| 1990's | 11 (20.37) | 18.2507 |
| 2000's | 16 (29.63) | 29.6817 |
| 2010's | 13 (24.07) | 24.3611 |
| 2020's | 9 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Nourbakhsh, B | 3 |
| Bradley, L | 1 |
| Khodaie, F | 1 |
| Naser Moghadasi, A | 1 |
| Kazemi, AH | 1 |
| Zhao, B | 1 |
| Rocca, MA | 2 |
| Valsasina, P | 2 |
| Lamanna, MT | 1 |
| Colombo, B | 2 |
| Martinelli, V | 2 |
| Filippi, M | 2 |
| Perez, DQ | 1 |
| Espiritu, AI | 1 |
| Jamora, RDG | 1 |
| Revirajan, N | 2 |
| Morris, B | 1 |
| Cordano, C | 1 |
| Creasman, J | 1 |
| Manguinao, M | 1 |
| Krysko, K | 1 |
| Rutatangwa, A | 1 |
| Auvray, C | 1 |
| Aljarallah, S | 1 |
| Jin, C | 1 |
| Mowry, E | 1 |
| McCulloch, C | 1 |
| Waubant, E | 3 |
| Bourdette, D | 1 |
| Grieb, P | 1 |
| Świątkiewicz, M | 1 |
| Prus, K | 1 |
| Rejdak, K | 1 |
| Yang, TT | 1 |
| Wang, L | 1 |
| Deng, XY | 1 |
| Yu, G | 1 |
| Ledinek, AH | 1 |
| Sajko, MC | 1 |
| Rot, U | 1 |
| Hamonet, C | 1 |
| Césaro, P | 1 |
| White, CM | 1 |
| van Doorn, PA | 2 |
| Garssen, MP | 2 |
| Stockley, RC | 1 |
| Mücke, M | 1 |
| Cuhls, H | 1 |
| Peuckmann-Post, V | 1 |
| Minton, O | 1 |
| Stone, P | 1 |
| Radbruch, L | 2 |
| Santarnecchi, E | 1 |
| Rossi, S | 1 |
| Bartalini, S | 1 |
| Cincotta, M | 1 |
| Giovannelli, F | 1 |
| Tatti, E | 1 |
| Ulivelli, M | 1 |
| Peuckmann, V | 1 |
| Elsner, F | 1 |
| Krumm, N | 1 |
| Trottenberg, P | 1 |
| Kirshbaum, M | 1 |
| Tejani, AM | 1 |
| Wasdell, M | 1 |
| Spiwak, R | 1 |
| Rowell, G | 1 |
| Nathwani, S | 1 |
| Induruwa, I | 1 |
| Constantinescu, CS | 1 |
| Gran, B | 1 |
| Shaygannejad, V | 1 |
| Janghorbani, M | 1 |
| Ashtari, F | 1 |
| Zakeri, H | 1 |
| Foroughipour, M | 1 |
| Bahrami Taghanaki, HR | 1 |
| Saeidi, M | 1 |
| Khazaei, M | 1 |
| Sasannezhad, P | 1 |
| Shoeibi, A | 1 |
| Taus, C | 2 |
| Giuliani, G | 2 |
| Pucci, E | 2 |
| D'Amico, R | 2 |
| Solari, A | 2 |
| Bakshi, R | 1 |
| Iwasaki, Y | 1 |
| Iguchi, H | 1 |
| Ichikawa, Y | 1 |
| Igarashi, O | 1 |
| Kawabe, S | 1 |
| Kiyozuka, T | 1 |
| Maruyama, M | 1 |
| Ikeda, K | 1 |
| Fujioka, T | 1 |
| Tomassini, V | 1 |
| Pozzilli, C | 1 |
| Onesti, E | 1 |
| Pasqualetti, P | 1 |
| Marinelli, F | 1 |
| Pisani, A | 1 |
| Fieschi, C | 1 |
| Zifko, UA | 1 |
| Schwid, SR | 1 |
| Murray, TJ | 2 |
| Schmitz, PI | 1 |
| Merkies, IS | 1 |
| Jacobs, BC | 1 |
| van der Meché, FG | 1 |
| Debouverie, M | 1 |
| Pittion, S | 1 |
| Boërio, D | 1 |
| Lefaucheur, JP | 1 |
| Hogrel, JY | 1 |
| Créange, A | 1 |
| Branãs, P | 2 |
| Benito-León, J | 1 |
| Martínez-Martín, P | 1 |
| Frades, B | 1 |
| Martínez-Ginés, ML | 1 |
| de Andrés, C | 1 |
| Meca-Lallana, JE | 1 |
| Antigüedad, AR | 1 |
| Huete-Antón, B | 1 |
| Rodríguez-García, E | 1 |
| Ruiz-Martínez, J | 1 |
| Lapierre, Y | 1 |
| Hum, S | 1 |
| Krupp, LB | 3 |
| Coyle, PK | 2 |
| Doscher, C | 2 |
| Miller, A | 1 |
| Cross, AH | 1 |
| Jandorf, L | 1 |
| Halper, J | 1 |
| Johnson, B | 1 |
| Morgante, L | 1 |
| Grimson, R | 1 |
| Stein, DP | 1 |
| Dambrosia, JM | 1 |
| Dalakas, MC | 1 |
| Mitchell, G | 1 |
| Geisler, MW | 1 |
| Sliwinski, M | 1 |
| Masur, DM | 1 |
| Poser, CM | 1 |
| Dulli, D | 1 |
| Schutta, H | 1 |
| Huete, B | 1 |
| Varona, L | 1 |
| Zimmermann, C | 1 |
| Hohlfeld, R | 1 |
| Sailer, M | 1 |
| Heinze, HJ | 1 |
| Schoenfeld, MA | 1 |
| Hauser, U | 1 |
| Smid, HG | 1 |
| Jordan, R | 1 |
| Fry-Smith, A | 1 |
| Burls, A | 1 |
| Hyde, C | 1 |
| Christodoulou, C | 1 |
| Chiba, S | 1 |
| Ito, M | 1 |
| Matsumoto, H | 1 |
| Wiggs, JW | 1 |
| Dunn, MG | 1 |
| Cohen, RA | 1 |
| Fisher, M | 1 |
| Rosenberg, GA | 1 |
| Appenzeller, O | 1 |
| Potvin, AR | 1 |
| Albers, JW | 1 |
| Repa, BS | 1 |
| Henderson, WG | 1 |
| Walker, JE | 1 |
| Stribley, RF | 1 |
| Tourtellotte, WW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis[NCT03185065] | Phase 3 | 141 participants (Actual) | Interventional | 2017-10-04 | Completed | ||
| A PILOT STUDY OF INTRAVENOUS, SUBANESTHETIC DOSE OF KETAMINE VS PLACEBO, A CROSSOVER DESIGN, FOR MULTIPLE SCLEROSIS RELATED FATIGUE[NCT06064162] | Early Phase 1 | 20 participants (Anticipated) | Interventional | 2023-10-31 | Not yet recruiting | ||
| Observational Study of the Effect of Ozanimod on Fatigue in Multiple Sclerosis Patients[NCT05319093] | 40 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| Feasibility Study of Adjunctive Bright Light Therapy (BLT) for Amelioration of Fatigue in Chinese Cancer Patients Admitted to a Palliative Care Unit[NCT04525924] | 42 participants (Anticipated) | Interventional | 2020-08-01 | Recruiting | |||
| Self-Management Program Based on Physical Exercises for People With Multiple Sclerosis With Mild Neurological Impairment: A Randomized Controlled Trial[NCT02607020] | 100 participants (Anticipated) | Interventional | 2015-12-31 | Recruiting | |||
| Multicenter Study, Randomized, Parallel Group Controlled, Testing the Effectiveness of a Behavioral Cognitive Therapy (BCT) vs Usual Local Practice on the Fatigue of Patients With Relapsing Remittent Multiple Sclerosis (RRMS)[NCT03758820] | 105 participants (Actual) | Interventional | 2017-05-31 | Completed | |||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Continuous Positive Airway Pressure for Fatigue Treatment in Patients With Multiple Sclerosis and Obstructive Sleep Apnea[NCT01563900] | 0 participants (Actual) | Interventional | 2012-02-29 | Withdrawn (stopped due to Was unable to recruit subjects) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants will answer yes or no to this question: Taken into consideration the possible benefits and/or disadvantages of this medication, would you choose it, going forward to treat your MS fatigue?. The number of participants who answered Yes to this question is reported here." (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 39 |
| Amantadine | 41 |
| Modafinil | 55 |
| Methylphenidate | 55 |
ESS score during the fifth week of treatment period. The ESS score can range from 0 to 24. The higher the score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 9.4 |
| Amantadine | 9.3 |
| Modafinil | 8.3 |
| Methylphenidate | 8.8 |
MFIS score during the fifth week of treatment period. The total score of the MFIS ranges from 0 to 84. Higher scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 40.6 |
| Amantadine | 41.3 |
| Modafinil | 39.0 |
| Methylphenidate | 38.6 |
Neuro-QoL Item Bank - Fatigue T score during the fifth week of treatment period. T-score distributions rescale raw scores into standardized scores with a mean of 50 and a standard deviation (SD) of 10. Higher T-scores denote more severe fatigue. (NCT03185065)
Timeframe: Week 5 of each treatment period
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Placebo | 53.1 |
| Amantadine | 53.0 |
| Modafinil | 52.5 |
| Methylphenidate | 52.0 |
19 reviews available for amantadine and Fatigue
| Article | Year |
|---|---|
Efficacy and safety of amantadine for the treatment of fatigue in multiple sclerosis: a systematic review and meta-analysis.
Topics: Amantadine; Fatigue; Female; Humans; Male; Multiple Sclerosis | 2020 |
Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
Topics: 4-Aminopyridine; Amantadine; Central Nervous System Stimulants; Dopamine Agents; Drug Therapy; Fatig | 2017 |
Interventions for fatigue in peripheral neuropathy.
Topics: Adult; Amantadine; Ascorbic Acid; Charcot-Marie-Tooth Disease; Child; Fatigue; Guillain-Barre Syndro | 2014 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Carnitine; Central Nervous System Stimulants; Chronic Disea | 2015 |
Pharmacological treatments for fatigue associated with palliative care.
Topics: Adult; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Fatigue; Humans; Kidney | 2010 |
Pharmacologic treatments for fatigue associated with palliative care.
Topics: Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Evidence-Based Medicine; Fatigu | 2011 |
Carnitine for fatigue in multiple sclerosis.
Topics: Acetylcarnitine; Adult; Amantadine; Fatigue; Humans; Multiple Sclerosis; Randomized Controlled Trial | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Fatigue in multiple sclerosis - a brief review.
Topics: Amantadine; Atrophy; Benzhydryl Compounds; Brain; Clinical Trials as Topic; Cognitive Behavioral The | 2012 |
Amantadine for fatigue in multiple sclerosis.
Topics: Amantadine; Antiviral Agents; Cross-Over Studies; Dopamine Agents; Fatigue; Humans; Multiple Scleros | 2003 |
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple | 2003 |
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple | 2003 |
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple | 2003 |
Fatigue associated with multiple sclerosis: diagnosis, impact and management.
Topics: Amantadine; Central Nervous System Stimulants; Fatigue; Humans; Magnetic Resonance Imaging; Multiple | 2003 |
Management of fatigue in patients with multiple sclerosis.
Topics: Amantadine; Antidepressive Agents; Benzhydryl Compounds; Central Nervous System Stimulants; Clinical | 2004 |
[Pathophysiology and treatment of fatigue in multiple sclerosis].
Topics: 4-Aminopyridine; Acute Disease; Amantadine; Amifampridine; Asthenia; Benzhydryl Compounds; Central N | 2006 |
Amantadine for fatigue in multiple sclerosis.
Topics: Amantadine; Antiviral Agents; Cross-Over Studies; Dopamine Agents; Fatigue; Humans; Multiple Scleros | 2007 |
Treating fatigue.
Topics: Amantadine; Central Nervous System Stimulants; Comorbidity; Diagnosis, Differential; Dopamine Agents | 2007 |
Update on multiple sclerosis therapy.
Topics: Amantadine; Baclofen; Fatigue; Humans; Immunosuppression Therapy; Interferons; Multiple Sclerosis; M | 1993 |
['Fatigue' in multiple sclerosis].
Topics: Amantadine; Aminopyridines; Disease Progression; Fatigue; Female; Humans; Male; Multiple Sclerosis; | 1999 |
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.
Topics: Amantadine; Central Nervous System Stimulants; Cost-Benefit Analysis; Dopamine Agents; Evidence-Base | 2000 |
Fatigue in multiple sclerosis.
Topics: Amantadine; Autoimmune Diseases; Benzhydryl Compounds; Brain; Case Management; Central Nervous Syste | 2001 |
Quantitative evaluation of neuropharmacological trials.
Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin | 1974 |
18 trials available for amantadine and Fatigue
| Article | Year |
|---|---|
Effectiveness of acupuncture for fatigue in patients with relapsing-remitting multiple sclerosis: a randomized controlled trial.
Topics: Acupuncture Therapy; Amantadine; Fatigue; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing- | 2023 |
Functional connectivity modifications in monoaminergic circuits occur in fatigued MS patients treated with fampridine and amantadine.
Topics: Amantadine; Brain; Brain Mapping; Dopamine; Fatigue; Humans; Magnetic Resonance Imaging; Multiple Sc | 2023 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.
Topics: Adult; Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Drug | 2021 |
Cortico-subcortical functional connectivity modifications in fatigued multiple sclerosis patients treated with fampridine and amantadine.
Topics: 4-Aminopyridine; Amantadine; Brain; Fatigue; Humans; Magnetic Resonance Imaging; Multiple Sclerosis | 2021 |
Treatment of fatigue with methylphenidate, modafinil and amantadine in multiple sclerosis (TRIUMPHANT-MS): Study design for a pragmatic, randomized, double-blind, crossover clinical trial.
Topics: Amantadine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Fatigue; Hum | 2018 |
Evaluating the effects of amantadin, modafinil and acetyl-L-carnitine on fatigue in multiple sclerosis--result of a pilot randomized, blind study.
Topics: Acetylcarnitine; Adult; Amantadine; Benzhydryl Compounds; Drug Combinations; Fatigue; Female; Humans | 2013 |
Comparison of the effect of aspirin and amantadine for the treatment of fatigue in multiple sclerosis: a randomized, blinded, crossover study.
Topics: Adult; Amantadine; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cross | 2012 |
Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial.
Topics: Acetylcarnitine; Adult; Amantadine; Analgesics, Non-Narcotic; Analysis of Variance; Confidence Inter | 2004 |
Amantadine for treatment of fatigue in Guillain-Barre syndrome: a randomised, double blind, placebo controlled, crossover trial.
Topics: Adult; Aged; Aged, 80 and over; Amantadine; Antiviral Agents; Anxiety; Cross-Over Studies; Depressio | 2006 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Central Nervous System Stimulants; Double-Blind | 1995 |
A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome.
Topics: Amantadine; Double-Blind Method; Fatigue; Humans; Postpoliomyelitis Syndrome; Surveys and Questionna | 1995 |
The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.
Topics: Adolescent; Adult; Amantadine; Analysis of Variance; Attention; Central Nervous System Stimulants; C | 1996 |
Amantadine influences cognitive processing in patients with multiple sclerosis.
Topics: Adult; Amantadine; Attention; Brain; Cognition; Dopamine Agents; Double-Blind Method; Evoked Potenti | 2000 |
Amantadine treatment of fatigue associated with multiple sclerosis.
Topics: Adult; Amantadine; Circadian Rhythm; Fatigue; Female; Humans; Male; Middle Aged; Multiple Sclerosis; | 1989 |
A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. The Canadian MS Research Group.
Topics: Activities of Daily Living; Adult; Amantadine; Clinical Trials as Topic; Depression; Double-Blind Me | 1987 |
Amantadine, fatigue, and multiple sclerosis.
Topics: Amantadine; beta-Endorphin; beta-Lipotropin; Disability Evaluation; Fatigue; Humans; Lactates; Lacti | 1988 |
Amantadine therapy for fatigue in multiple sclerosis.
Topics: Amantadine; Clinical Trials as Topic; Fatigue; Humans; Multiple Sclerosis | 1985 |
Quantitative evaluation of neuropharmacological trials.
Topics: Activities of Daily Living; Age Factors; Amantadine; Clinical Trials as Topic; Dihydroxyphenylalanin | 1974 |
18 other studies available for amantadine and Fatigue
| Article | Year |
|---|---|
Serious side effects of amantadine: Rethinking the benefits and risks of medications for MS fatigue.
Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Risk Assessment | 2021 |
Delayed amantadine toxicity causing apparent progression of multiple sclerosis.
Topics: Amantadine; Disease Progression; Fatigue; Female; Humans; Multiple Sclerosis; Multiple Sclerosis, Ch | 2021 |
Are drugs for multiple sclerosis fatigue just placebos?
Topics: Amantadine; Double-Blind Method; Fatigue; Humans; Methylphenidate; Modafinil; Multiple Sclerosis; Ph | 2021 |
Amantadine for COVID-19.
Topics: Amantadine; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Fatigue; Humans; Multiple Sclerosis | 2021 |
[Ehlers-Danlos and dystonia. Positive effects of amantadine].
Topics: Adult; Amantadine; Antiparkinson Agents; Craniocerebral Trauma; Dystonia; Ehlers-Danlos Syndrome; Fa | 2014 |
Neurophysiological Correlates of Central Fatigue in Healthy Subjects and Multiple Sclerosis Patients before and after Treatment with Amantadine.
Topics: Adult; Amantadine; Evoked Potentials, Motor; Fatigue; Female; Fingers; Humans; Male; Middle Aged; Mo | 2015 |
Amantadine and the place of acupuncture in the treatment of fatigue in patients with multiple sclerosis: an observational study.
Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Amantadine; Child; Drug Resistance; Fatigue; Female; H | 2013 |
Fatigue and depression are associated with poor quality of life in ALS.
Topics: Adaptation, Psychological; Amantadine; Amyotrophic Lateral Sclerosis; Caregivers; Cross-Sectional St | 2003 |
Treating fatigue in patients with MS: one step forward, one step back.
Topics: Amantadine; Aspirin; Benzhydryl Compounds; Central Nervous System; Central Nervous System Stimulants | 2005 |
[Fatigue and episodic exhaustion as a feature of multiple sclerosis].
Topics: 4-Aminopyridine; Amantadine; Amifampridine; Benzhydryl Compounds; Fatigue; Humans; Hypnotics and Sed | 2006 |
Impact of fatigue in multiple sclerosis: the Fatigue Impact Scale for Daily Use (D-FIS).
Topics: Adolescent; Adult; Aged; Amantadine; Benzhydryl Compounds; Central Nervous System Stimulants; Dopami | 2007 |
Fatigue in MS.
Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis | 1996 |
Fatigue in MS.
Topics: Amantadine; Fatigue; Humans; Multiple Sclerosis; Pemoline | 1996 |
[Insomnia during treatment with amantadine].
Topics: Adult; Amantadine; Dopamine Agents; Fatigue; Humans; Male; Multiple Sclerosis; Sleep Initiation and | 1997 |
[Therapeutic indications for managing symptoms: fatigue].
Topics: Amantadine; Aminopyridines; Double-Blind Method; Fatigue; Humans; Multiple Sclerosis; Randomized Con | 2001 |
Amantadine treatment for refractory pain and fatigue in patients with multiple sclerosis.
Topics: Adult; Amantadine; Fatigue; Female; Humans; Male; Multiple Sclerosis; Pain | 1992 |
Amantidine, the old anti-Parkinson medication, being useful in the fatigue syndrome that often accompanies multiple sclerosis.
Topics: Amantadine; Fatigue; Fatigue Syndrome, Chronic; Humans; Male; Middle Aged; Multiple Sclerosis; Parki | 1991 |
Post-polio fatigue treated with amantadine.
Topics: Amantadine; Fatigue; Humans; Postpoliomyelitis Syndrome | 1991 |